Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control · 2015
[Curative effect of anti-HBV treatment in advanced schistosomiasis patients with ascites and HIBV infection].
Клиническое исследованиеАннотация на английскомСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luo Fu-jun, Yao Zuo-ping
Аннотация
OBJECTIVE: To improve the curative effect of advanced schistosomiasis patients with ascites and HBV infection.
METHODS: A total of 27 advanced schistosomiasis patients with ascites and HBV infection were selected as a trial group and given with anti-HBV treatment, and 31 corresponding patients were as the controls and did not received anti-HBV treatment from February 2003 to December 2012.
RESULTS: The incidence of ascites recurrence, spontaneous peritonitis, hepatic encephalopathy, hepatorenal syndrome, upper gastrointestinal bleeding, and primary liver cancer in the trial group were significantly lower than those in the control group. The detection indexes of liver function, renal function and prothrombin time in the trial group were superior to those in the control group. The mortality in the treatment group was also significantly lower than that in the control group.
CONCLUSION: The anti-HBV treatment in the advanced schistosomiasis patients with ascites and HBV infection can obviously improve their physical conditions, the survival rate, and their life qualities.
METHODS: A total of 27 advanced schistosomiasis patients with ascites and HBV infection were selected as a trial group and given with anti-HBV treatment, and 31 corresponding patients were as the controls and did not received anti-HBV treatment from February 2003 to December 2012.
RESULTS: The incidence of ascites recurrence, spontaneous peritonitis, hepatic encephalopathy, hepatorenal syndrome, upper gastrointestinal bleeding, and primary liver cancer in the trial group were significantly lower than those in the control group. The detection indexes of liver function, renal function and prothrombin time in the trial group were superior to those in the control group. The mortality in the treatment group was also significantly lower than that in the control group.
CONCLUSION: The anti-HBV treatment in the advanced schistosomiasis patients with ascites and HBV infection can obviously improve their physical conditions, the survival rate, and their life qualities.